302 related articles for article (PubMed ID: 37704428)
1. Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans.
Doi T; Langsted A; Nordestgaard BG
J Atheroscler Thromb; 2023 Nov; 30(11):1525-1546. PubMed ID: 37704428
[TBL] [Abstract][Full Text] [Related]
2. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
3. Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström BN; Wulff AB; Pedersen KM; Nordestgaard BG
Curr Atheroscler Rep; 2023 Nov; 25(11):795-803. PubMed ID: 37768410
[TBL] [Abstract][Full Text] [Related]
4. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
5. Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood.
Shoar S; Ikram W; Shah AA; Farooq N; Gouni S; Khavandi S; Tabibzadeh E; Khavandi S
Rev Cardiovasc Med; 2021 Jun; 22(2):295-299. PubMed ID: 34258898
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
Zhou R; Stouffer GA; Smith SC
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
[TBL] [Abstract][Full Text] [Related]
7. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
Nordestgaard BG; Langlois MR; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
Atherosclerosis; 2020 Feb; 294():46-61. PubMed ID: 31928713
[TBL] [Abstract][Full Text] [Related]
8. World Heart Federation Cholesterol Roadmap 2022.
Ray KK; Ference BA; Séverin T; Blom D; Nicholls SJ; Shiba MH; Almahmeed W; Alonso R; Daccord M; Ezhov M; Olmo RF; Jankowski P; Lanas F; Mehta R; Puri R; Wong ND; Wood D; Zhao D; Gidding SS; Virani SS; Lloyd-Jones D; Pinto F; Perel P; Santos RD
Glob Heart; 2022; 17(1):75. PubMed ID: 36382159
[TBL] [Abstract][Full Text] [Related]
9. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
Xue H; Zhang M; Liu J; Wang J; Ren G
Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
[TBL] [Abstract][Full Text] [Related]
10. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.
Borén J; Williams KJ
Curr Opin Lipidol; 2016 Oct; 27(5):473-83. PubMed ID: 27472409
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
Nordestgaard BG
Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
[TBL] [Abstract][Full Text] [Related]
12. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
Makover ME; Shapiro MD; Toth PP
Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies.
Saeed A; Virani SS; Mulukutla S; Chow CK
Curr Diabetes Rev; 2021; 17(9):e011221190238. PubMed ID: 33438542
[TBL] [Abstract][Full Text] [Related]
14. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
[TBL] [Abstract][Full Text] [Related]
15. Dietary and Physiological Factors Affecting Lipid Metabolism and Cardiovascular Risk.
Yoshida H
J Nutr Sci Vitaminol (Tokyo); 2022; 68(Supplement):S119-S120. PubMed ID: 36436990
[TBL] [Abstract][Full Text] [Related]
16. Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors.
Dansinger ML; Williams PT; Superko HR; Schaefer EJ
Lipids Health Dis; 2019 Jul; 18(1):154. PubMed ID: 31311555
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
[TBL] [Abstract][Full Text] [Related]
18. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV
J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072
[TBL] [Abstract][Full Text] [Related]
19. Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study.
Yun SY; Rim JH; Kang H; Lee SG; Lim JB
Ann Lab Med; 2023 May; 43(3):237-243. PubMed ID: 36544335
[TBL] [Abstract][Full Text] [Related]
20. Remnant lipoproteins and atherosclerotic cardiovascular disease.
Tada H; Nohara A; Inazu A; Mabuchi H; Kawashiri MA
Clin Chim Acta; 2019 Mar; 490():1-5. PubMed ID: 30553862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
